IP Library Granted Patent US 11,717,440
Granted Patent B2
US 11,717,440 · App. 16/254,765 · Granted Aug 8, 2023

Method and device for treating eye disease

Inventors: Brandon Wei-Hsiang Kao (Placentia, CA); Adarsh Narayan Battu (Fremont, CA); Rui Jing Jiang (Lexington, MA)
Assignee: Avisi Technologies, Inc.
A61F9/00781A61F2220/0016A61F2230/0004A61F2230/0019A61F2230/0021A61F2230/0023
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,717,440
App. No.
16/254,765
Granted
Aug 8, 2023
Kind
B2
Abstract

Described herein is a device for lowering intraocular pressure, the device comprising a plate structure comprising an upper surface opposite a lower surface, the plate structure formed from a multi-directional plate having a plate thickness ranging from about 1 nm to about 1,000 nm.

Claims (19)

1. A method of reducing intraocular pressure comprising:

a) securing a treatment device to an eye, the treatment device comprising a continuous plate structure that enables aqueous humor to flow from a first end to a second end, the first end having a maximum width that is narrower than a maximum width of the second end, the treatment device comprising:

an uppermost surface opposite a lowermost surface, the uppermost surface including a plurality of open cells; and

a fluid pathway including a plurality of open channels formed into the lowermost surface, the plurality of open channels configured in an intersecting grid pattern extending from the first end to the second end,

wherein the treatment device enables aqueous humor to flow along the fluid pathway, thereby reducing intraocular pressure within the eye, and

wherein the first end of the treatment device is inserted into an anterior chamber of the eye and the second end of the treatment device is inserted into at least one of an uveoscleral outflow pathway, Schlemm's canal, a collector channel, a supraciliary space, a trabecular meshwork, a subconjunctival space, or a suprachoroidal space of the eye.

2. The method according to claim 1 , wherein the treatment device is secured onto a sclera of the eye.

3. The method according to claim 2 , wherein after step a) the treatment device is located at an implant position in the eye such that a first major exposed surface of the plate structure faces a conjunctiva of the eye and a second major exposed surface of the plate structure faces the sclera of the eye.

4. The method according to claim 1 , wherein the intersecting grid pattern includes a hexagonal grid pattern.

5. The method according to claim 1 , wherein after step a), at least a portion of the treatment device is located between two adjacent eye muscles, wherein at least a portion of the treatment device is located between the lateral rectus muscle and the superior rectus muscle.

6. The method according to claim 1 , wherein the first end of the treatment device is inserted into an anterior chamber of the eye and the second end of the treatment device is inserted between two adjacent eye muscles.

7. A method of reducing intraocular pressure comprising:

causing a second end of a treatment device to be secured within drainage tissue of an eye of a patient; and

causing a first end of the treatment device to be secured within an anterior chamber of the eye for receiving excess aqueous humor, the first end of the treatment device having a maximum width that is narrower than a maximum width of the second end of the treatment device,

wherein the treatment device, including the first end and the second end, includes a continuous plate structure having an uppermost surface opposite a lowermost surface and a plurality of open channels formed into one of the uppermost surface or the lowermost surface, the plurality of open channels configured in an intersecting grid pattern extending from the first end to the second end of the treatment device, the continuous plate structure further comprising a plurality of open cells formed into the other of the uppermost surface and lowermost surface,

wherein the plurality of open channels are configured in an intersecting grid pattern that defines a fluid pathway,

wherein the treatment device enables aqueous humor to flow along the fluid pathway, thereby reducing intraocular pressure within the eye, and

wherein the drainage tissue includes at least one of an uveoscleral outflow pathway, Schlemm's canal, a collector channel, a supraciliary space, a trabecular meshwork, a subconjunctival space, or a suprachoroidal space of the eye.

8. The method according to claim 7 , wherein the second end of the treatment device is inserted between two adjacent eye muscles.

Assignments (2)
CHANGE OF NAME Recorded Jan 4, 2021
From: AVISI TECHNOLOGIES, LLC
To: AVISI TECHNOLOGIES, INC.
Reel/Frame 054898/0287 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 23, 2019
From: KAO, BRANDON WEI-HSIANG; BATTU, ADARSH NARAYAN; JIANG, RUI JING
To: AVISI TECHNOLOGIES, LLC
Reel/Frame 048104/0077 →
Continuity (3)
Provisional Application 62794139 · Jan 18, 2019
Provisional Application 62620922 · Jan 23, 2018
Related Publication 20190224047A1 · Jul 25, 2019
Cited By (1)
US 12,472,096